Prolymphocytic LeukemiaSymptoms, Doctors, Treatments, Advances & More
Learn About Prolymphocytic Leukemia
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Michael Hallek practices practicing medicine in Koeln, Germany. Mr. Hallek is rated as an Elite expert by MediFind in the treatment of Prolymphocytic Leukemia. He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Leukemia, Bone Marrow Transplant, and Bone Graft.
Stephan Stilgenbauer practices practicing medicine in Ulm, Germany. Mr. Stilgenbauer is rated as an Elite expert by MediFind in the treatment of Prolymphocytic Leukemia. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Leukemia, Bone Marrow Transplant, and Bone Graft.
Claire Dearden practices practicing medicine in London, United Kingdom. Ms. Dearden is rated as an Elite expert by MediFind in the treatment of Prolymphocytic Leukemia. She is also highly rated in 13 other conditions, according to our data. Her clinical expertise encompasses Hairy Cell Leukemia (HCL), Prolymphocytic Leukemia, Chronic T-Cell Leukemia (CTCL), Splenectomy, and Bone Marrow Transplant.
Summary: This phase II trial tests how well ruxolitinib as a maintenance medication works to prevent relapse and graft-versus-host disease (GVHD) for patients who have undergone stem cell transplantation for T-cell lymphoma. GVHD is a common problem that may occur after a blood stem cell transplant. The graft is the donor blood cells that patients get during the transplant. The host is the person receiving...
Summary: This study will test the safety of ruxolitinib, given at one dose that does not change, and duvelisib, given at different doses, to find out what effects, if any, the study treatment has on people with relapsed or refractory NK-cell or T-cell lymphoma. This study has three parts: dose escalation (Part 1), dose expansion (Part 2), and TFH/T-PLL cohort expansion (Part 3).